申请人:Shinkai Hisashi
公开号:US20080027109A1
公开(公告)日:2008-01-31
The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I):
wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X
1
, X
2
, X
3
, and X
4
may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO
2
—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.
本发明提供了一种CETP活性抑制剂,其包含以下式子(I)表示的化合物作为活性成分:其中R表示直链或支链烷基;直链或支链烯基;低卤代烷基;取代或未取代环烷基;取代或未取代环烯基;取代或未取代环烷基烷基;取代或未取代芳基;或取代或未取代杂环基,X1、X2、X3和X4可以相同或不同,每个表示氢原子、卤素原子、低烷基、低卤代烷基;低烷氧基;氰基;硝基;酰基;或芳基,Y表示—CO—或—SO2—,Z表示氢原子或巯基保护基,或其前药化合物,药学上可接受的盐或其水合物或溶剂化物。式(I)所表示的化合物可以通过选择性抑制CETP活性增加HDL并同时降低LDL,因此预计可作为一种新型的预防或治疗动脉粥样硬化或高脂血症的药物。